Genentech and Leukemia & Lymphoma Society Award $1.3m to Weill-Cornell Medicine for Low-Income & Minority Access to Research as a Care Option

Genentech & Leukemia & Lymphoma Society Award $1.3m to Weill-Cornell Medicine for Low-Income & Minority Access to Research as a Care Option

Genentech, part of Roche, along with the Leukemia & Lymphoma Society (LLS), awarded complementary grants to Weill Cornell Medicine to support a new program linking social and racial disparities while boosting access to clinical trials for underserved patients fighting blood cancers who live in Brooklyn and Queens. A research team has been established to capitalize on the grant funds, including a $678,000 Genentech Health Equity Innovation Fund award and $622,000 from LLS- IMPACT (Influential Medicine Providing Access to Clinical Trials) research grants awarded in April. Led by Dr. John Leonard, senior associate dean for innovation and initiatives, along with Dr. Erica Phillips, associate director of community outreach and engagement at the Sandra Edward Meyer Cancer Center, the team benefits from a total of $1.3 million over five years to establish the Blood Cancer Research Initiative Developing Greater Engagement with Community Patients (BRIDGE) program.

TrialSite follows with a brief breakdown of this important funded program supporting the emerging clinical research as a care option paradigm. Jane Langille, a freelance writer for Weill Cornell Medicine, recently authore...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee